Amarin Corporation plc

NASDAQ•AMRN

CEO: Mr. Aaron D. Berg

Sector: Healthcare

Industry: Biotechnology

Listing Date: 1993-04-01

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Contact Information

Iconic Offices, The Greenway, Block C Ardilaun Court St Stephens Green, Dublin, 112-114, Ireland

353-0-166-99020

www.amarincorp.com

Market Cap

$330.20M

P/E (TTM)

-171.2

17.5

Dividend Yield

52W High

$20.90

52W Low

$7.00

52W Range

65%

Rank57Top 83.3%

2.4

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 2.4 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$19.44M+0.00%

4-Quarter Trend

EPS

-$0.00+0.00%

4-Quarter Trend

FCF

$8.55M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Net Loss Significantly Reduced Net loss narrowed to $38.8M in 2025 from $82.2M in 2024, showing substantial operational improvement.

Gross Margin Expansion Achieved Gross margin increased to $120.9M in 2025, up from $81.4M in 2024, driven by lower Cost of Goods Sold.

Licensing Revenue Increased Licensing and royalty revenue rose 29% to $30.9M, primarily due to recognition of the Recordati Licensing Agreement upfront payment.

Risk Factors

Heavy Product Revenue Dependence Business remains substantially dependent on VASCEPA sales, limiting financial flexibility if market developments are negative.

U.S. Generic Competition Intensifies Increasing generic versions of icosapent ethyl in the U.S. continue to materially affect VASCEPA net product revenue.

Ongoing Antitrust Litigation Exposure Company faces costly and lengthy antitrust litigation regarding API supply, potentially resulting in significant fines or injunctions.

Outlook

Restructuring Cost Savings Expected Global Restructuring Plan implemented in June 2025 expects to reduce operating costs by approximately $70M annually moving forward.

Focus on International Expansion Continue assessing partnership opportunities outside the U.S. and Recordati territory for VASCEPA commercialization growth.

Future Capital Requirements Assessed Additional capital may be required to fund planned VASCEPA promotion and potential international commercialization efforts.

Peer Comparison

Revenue (TTM)

AMRN

$183.87M

-19.6%

CLLS

$75.27M

+158.9%

AUTL

$51.13M

+406.7%

Gross Margin (Latest Quarter)

ALT

57207.7%

-299200.0pp

AMRN

119.2%

+7.3pp

KRRO

100.0%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
RAPT	$959.26M	-14.8	-61.8%	1.6%
DSGN	$569.07M	-8.2	-32.7%	0.3%
DBVT	$563.12M	-3.6	-295.2%	14.5%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

-22.7%

Growth Under Pressure

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

50%

Cash Flow Needs Attention

Deep Research

Next earnings:Mar 11, 2026

EPS:-$1.27

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data